title: Dysregulated relationship of inflammation and oxidative stress in major depression.
abstract: Chronic inflammation and oxidative stress have been implicated in the pathophysiology of Major Depressive Disorder (MDD), as well as in a number of chronic medical conditions. The aim of this study was to examine the relationship between peripheral inflammatory and oxidative stress markers in un-medicated subjects with MDD compared to non-depressed healthy controls and compared to subjects with MDD after antidepressant treatment. We examined the relationships between IL-6, IL-10, and the IL-6/IL-10 inflammatory ratio vs. F2-isoprostanes (F2-IsoP), a marker of oxidative stress, in un-medicated MDD patients (n=20) before and after 8 weeks of open-label sertraline treatment (n=17), compared to healthy non-depressed controls (n=20). Among the un-medicated MDD subjects, F2-IsoP concentrations were positively correlated with IL-6 concentrations (p<0.05) and were negatively correlated with IL-10 concentrations (p<0.01). Accordingly, F2-IsoP concentrations were positively correlated with the ratio of IL-6/IL-10 (p<0.01). In contrast, in the control group, there were no significant correlations between F2-IsoPs and either cytokine or their ratio. After MDD subjects were treated with sertraline for 8 weeks, F2-IsoPs were no longer significantly correlated with IL-6, IL-10 or the IL-6/IL-10 ratio. These data suggest oxidative stress and inflammatory processes are positively associated in untreated MDD. Our findings are consistent with the hypothesis that the homeostatic buffering mechanisms regulating oxidation and inflammation in healthy individuals become dysregulated in untreated MDD, and may be improved with antidepressant treatment. These findings may help explain the increased risk of comorbid medical illnesses in MDD.
authors.affiliation: Department of Psychiatry, University of California, San Francisco, San Francisco, CA, USA.
authors.forename: B J
authors.initials: BJ
authors.lastname: Rawdin
authors.forename: S H
authors.initials: SH
authors.lastname: Mellon
authors.forename: F S
authors.initials: FS
authors.lastname: Dhabhar
authors.forename: E S
authors.initials: ES
authors.lastname: Epel
authors.forename: E
authors.initials: E
authors.lastname: Puterman
authors.forename: Y
authors.initials: Y
authors.lastname: Su
authors.forename: H M
authors.initials: HM
authors.lastname: Burke
authors.forename: V I
authors.initials: VI
authors.lastname: Reus
authors.forename: R
authors.initials: R
authors.lastname: Rosser
authors.forename: S P
authors.initials: SP
authors.lastname: Hamilton
authors.forename: J C
authors.initials: JC
authors.lastname: Nelson
authors.forename: O M
authors.initials: OM
authors.lastname: Wolkowitz
mesh_terms: D000328:Adult; D000928:Antidepressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy / Q000378:metabolism*; D005260:Female; D006801:Humans; D007249:Inflammation / Q000378:metabolism*; D016753:Interleukin-10 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects* / Q000502:physiology; D020280:Sertraline / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents; D015850:Interleukin-6; D016753:Interleukin-10; D020280:Sertraline